Comparison of perinatal and maternal outcomes of severe preeclampsia, eclampsia, and HELLP syndrome

Preeklampsı, eklampsi ve HELLP sendromu olgularında perinatal ve maternal sonuçların karşılaştırılması

Gökhan Yıldırım¹, Kemal Güngördük², Halil Aslan², Ahmet Gül², Mehmet Bayraktar², Yavuz Ceylan²

¹İstanbul Bakırköy Women's and Children's Hospital, İstanbul, Turkey
²Mardin Women's and Children's Hospital, Mardin, Turkey

Abstract

Objective: To compare maternal and perinatal outcomes in pregnancies complicated by severe preeclampsia, eclampsia, and HELLP (hemolysis, elevated liver enzyme levels, and low platelets) syndrome.

Materials and Methods: Maternal and neonatal charts of 1,222 consecutive pregnancies complicated by severe preeclampsia, eclampsia, or HELLP syndrome at our maternal-perinatal unit were reviewed. Patients were divided into three groups: 903 (73.9%) with severe preeclampsia, 123 (10.1%) with eclampsia, and 196 (16.0%) with HELLP syndrome.

Results: The overall incidence of adverse maternal outcome was 5.9%. The rates of adverse maternal outcomes for women with HELLP syndrome and eclampsia were higher than for severe preeclampsia (13.8% vs. 11.4% vs. 3.4%, respectively) (p=0.000). Birth weight was lower in patients with HELLP syndrome than in patients with eclampsia and severe preeclampsia (p=0.005). No significant difference in neonatal morbidity was found among the three groups. Perinatal mortality tended to be higher in the severe preeclampsia group than in the HELLP syndrome and eclampsia groups (p=0.231).

Conclusion: Pregnancy complicated by HELLP syndrome had significantly higher maternal morbidity than those with severe preeclampsia and eclampsia. Perinatal and neonatal outcomes in pregnancies complicated by severe preeclampsia, eclampsia, and HELLP syndrome were dependent on gestational age rather than being disease dependent. (J Turkish-German Gynecol Assoc 2011; 12: 90-6)

Key words: Severe preeclampsia, eclampsia, HELLP syndrome, perinatal and maternal outcome

Received: 6 March, 2011 Accepted: 1 May, 2011

Introduction

Hypertensive disorders during pregnancy represent a significant public health problem throughout the world, and preeclampsia is the most common of these disorders (1). Villar et al. reviewed available information on the incidence and prevalence of preeclampsia/eclampsia utilizing large epidemiological studies (2). They estimated that hypertension complicates approximately 5% of all pregnancies. Of these, approximately half are due to or associated with preeclampsia. Based on these estimates and case-fatality rates, they calculated that up to 40,000 women, mostly in developing countries, may die due to preeclampsia or eclampsia each year. The clinical course of severe preeclampsia results in progressive deterioration of both maternal and fetal conditions. Traditional management of severe preeclampsia has focused on maternal safety, with expedited delivery. Because these pregnancies are associated with high rates of maternal mor-

Address for Correspondence: Assoc. Dr. Kemal Güngördük, Mardin Women's and Children's Hospital, Mardin, Turkey
Phone: +90 212 660 84 94 e.mail: maidenkemal@yahoo.com
bility and mortality and with potential risks for the fetus, it is generally agreed that such patients should be delivered if the disease develops at >34 weeks of gestation (3, 4). In patients with severe preeclampsia at <34 weeks of gestation, several authors have suggested some form of expectant management in an attempt to prolong gestation and improve perinatal outcome (3-7). For patients with severe fetal growth restriction (FGR) with or without oligohydramnios or evidence of maternal organ dysfunction (eclampsia, HELLP syndrome), some authors have recommended steroids to enhance lung maturation, with delivery 48 hours after initiating steroid administration (3-9).

The main objective when managing severe preeclampsia, eclampsia, and HELLP syndrome is to reduce maternal mortality and morbidity rates. Current literature emphasizes an increased risk of adverse outcomes for patients with severe preeclampsia, eclampsia, and HELLP syndrome. However, few studies have compared perinatal and maternal outcomes in pregnancies complicated by severe preeclampsia, eclampsia, and HELLP syndrome.

**Materials and Methods**

The Bakirkoy Women and Children Education and Research Hospital in Istanbul, Turkey serves as a tertiary care facility for western Turkey, where there are approximately 14,000 deliveries annually. During the 6-year period from January 1, 2002 through December 2007, 1,222 of these pregnancies antenatally managed at this hospital were complicated by severe preeclampsia, eclampsia, and HELLP syndrome. This study was approved by the hospital’s Ethics Committee.

Women had severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure >160 mm/Hg or diastolic blood pressure >110 mm/Hg, headache, visual disturbances, epigastric or right-upper-quadrant pain, pulmonary edema, and proteinuria (urinary protein level >5 g/24 h). Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/mm³, serum lactate dehydrogenase <600 U/L, serum total bilirubin <1.2 mg/dL, and serum aspartate aminotransferase <70 U/L. Eclampsia was defined as tonic-clonic seizures occurring during a hypertensive pregnancy. Patients with any causes for convulsion other than eclampsia were excluded.

HELLP syndrome was divided into three classes by Martin et al. (11). They defined class 1 HELLP syndrome as a platelet nadir below 50,000/mm³, whereas those with platelet nadirs between 51,000 and 100,000/mm³ were defined as class 2. Class 3 HELLP syndrome represented patients with hepatocyte death but a higher platelet count nadir of 101,000-150,000/mm³.

Gestational age was determined using the best obstetric criteria, including either the last menstrual period or ultrasonography (where available) at <20 weeks gestation or both. On admission, hematocrit, hemoglobin, platelet count, and liver enzymes were determined, and 24-h urine collection was started. A hemogram and blood biochemistry tests were repeated daily or at a 2-day intervals. Fetal heart rate monitoring (FHR) was performed at least two to three times per day. Nifedipine and/or alfa-methyldopa were used as antihypertensive agents. An intravenous infusion of magnesium sulfate at a rate of 2 g/h was started, after a loading dose of 4.5 g for 10 min, in patients with persistently elevated systolic or diastolic blood pressure and/or prodromal symptoms and was continued postpartum for 24 h in severe preeclampsia and 48 h in eclampsia. Two doses of betamethasone (12 mg intramuscularly) were also given at 24 h intervals.

Maternal indications for delivery included persistent elevated blood pressure >160/110 mm Hg despite treatment with antihypertensive drugs, persistent or worsening symptoms, deteriorating renal function, severe ascites, abruptio placenta, oliguria, pulmonary edema, preterm labor, preterm rupture of membranes, evidence of class 1-2 HELLP syndrome, and eclampsia. Fetal indications for delivery included a non-reassuring fetal status as determined by the fetal heart rate tracing (decreased variability, repetitive late decelerations, or severe variable decelerations), FGR, oligohydramnios, severe abnormal umbilical artery Doppler findings such as absent or reverse end diastolic flow, and attainment of the 34th or ≥34th week of gestation on admission.

Oligohydramnios was diagnosed with an amniotic fluid index ≤5 cm or a two-diameter pocket <15 cm². FGR was defined as a birth weight below the 10th percentile for gestational age. The maternal variables studied included age, gravity, parity, gestational age at delivery, timing of eclampsia onset, and adverse maternal outcome. Maternal outcomes included abruptio placenta, acute renal failure (ARF), pulmonary edema, ascites, acute respiratory distress syndrome (ARDS), neurological deficits, visual changes, intracranial hemorrhage, and maternal death. ARF was diagnosed when oliguria or anuria in association with a creatinine clearance ≤20 mL/min was present with an elevated serum creatinine level ≥2 mg/dL. Pulmonary edema was assessed based on clinical findings and chest radiography. A diagnosis of severe ascites was made by estimation during an ultrasonographic examination, cesarean delivery, or laparotomy (≥1000 mL of fluid measured by a suction apparatus).

Neonatal and fetal medical records were reviewed for the following outcomes: FGR, oligohydramnios, mode of delivery, intranatal fetal death, perinatal (fetal death and early neonatal death at <7 postnatal days) and neonatal (postnatal 0-28 days) mortality, ARDS, grade 3-4 intraventricular hemorrhage (IVH), stage 2-3 necrotizing enterocolitis (NEC), sepsis, admission to the intensive care unit (ICU), duration of stay in the ICU, and duration of hospitalization. ARDS was defined by the presence of characteristic radiographic findings and oxygen requirements at 24 h. Grade 3 intraventricular hemorrhage was defined as hemorrhage with ventricular dilation, and grade 4 as hemorrhage with parenchymal involvement. NEC was defined by radiographic findings of grade 2 pneumatosis cystoides intestinalis and a grade 3 pneumoperitoneum. Intrauterine death and intrapartum loss of nonviable fetuses during pregnancy termination due to maternal indications were accepted as fetal death.
Data are presented as rates, percentiles, medians (interquartile ranges), and means±SDs. Statistical comparisons were performed using analysis of variance, Kruskal-Wallis test, and $\chi^2$ test, as appropriate. P-values < 0.05 were considered significant. Because double comparisons cannot be performed with the Kruskal-Wallis test, the groups significant in this analysis were compared as groups of two using the Mann-Whitney U-test. Levels of significance were evaluated with the Bonferroni correction ($n/a=0.05/3=0.017$), and $p<0.017$ was considered significant.

Results

During the study period, 1222 cases of severe preeclampsia, eclampsia, or HELLP syndrome were treated at our institute. Among these, 123 (10.1%) had eclampsia, 903 (73.9%) had severe preeclampsia, and 196 (16.0%) had HELLP syndrome (Fig. 1). This classification was determined based on the patients' initial presentation. Patients with HELLP syndrome and eclampsia were evaluated as the eclampsia group. Forty-one cases of eclampsia experienced HELLP syndrome. A total of 734 (60.0%) patients (601 with severe preeclampsia, 57 with eclampsia, and 76 with HELLP syndrome) were referred from surrounding hospitals and clinics, 297 (24.4%) were given antenatal care at our hospital (213 with preeclampsia, 35 with eclampsia, 49 with HELLP syndrome), and 191 (15.6%) patients received no antenatal care prior to admission (89 patients with severe preeclampsia, 31 with eclampsia, 71 with HELLP syndrome).

Table 1. Clinical characteristics in 3 study groups

<table>
<thead>
<tr>
<th>Severe Preeclampsia (n=903)</th>
<th>Eclampsia (n=123)</th>
<th>HELLP syndrome (n=196)</th>
<th>P</th>
<th>P1b</th>
<th>P2b</th>
<th>P3b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year, median, Q1-Q3)</td>
<td>27 (24-32)</td>
<td>25 (22-29)</td>
<td>28 (25-33)</td>
<td>&lt;0.0001*</td>
<td>&lt;0.0001</td>
<td>0.144</td>
</tr>
<tr>
<td>Gravidity (median, Q1-Q3)</td>
<td>2 (1-3)</td>
<td>1 (1-2)</td>
<td>2 (1-3)</td>
<td>0.0002*</td>
<td>0.0003</td>
<td>0.355</td>
</tr>
<tr>
<td>Parity (median, Q1-Q3)</td>
<td>0 (0-2)</td>
<td>0 (0-1)</td>
<td>1 (0-2)</td>
<td>0.0006*</td>
<td>0.0012</td>
<td>0.358</td>
</tr>
<tr>
<td>Nulliparity, %</td>
<td>49.8</td>
<td>35</td>
<td>53.1</td>
<td>0.004*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*aAccording to the Kruskal-Wallis test (triple comparison) $P<0.05$

*bMann-Whitney U test $P1=Severe Preeclampsia versus Eclampsia, P2=Severe preeclampsia versus HELLP syndrome, P3=Eclampsia versus HELLP Syndrome

Significant p value after Bonferroni correction $<0.017$

*According to $\chi^2$ test for trend

Table 2. Clinical characteristics in 3 study groups

<table>
<thead>
<tr>
<th>Maternal outcomes</th>
<th>Severe Preeclampsia (n=903)</th>
<th>Eclampsia (n=123)</th>
<th>HELLP syndrome (n=196)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal morbidity</td>
<td>35 (3.9%)</td>
<td>15 (12.2%)</td>
<td>29 (14.8%)</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>ARDS</td>
<td>4 (0.4%)</td>
<td>3 (2.4%)</td>
<td>1 (0.5%)</td>
<td>0.038</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>14 (1.6%)</td>
<td>5 (4.1%)</td>
<td>21 (10.7%)</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>Neurologic deficits</td>
<td>1 (0.8%)</td>
<td>3 (0.3%)</td>
<td>2 (1%)</td>
<td>0.0015</td>
</tr>
<tr>
<td>Visual change</td>
<td>6 (0.7%)</td>
<td>6 (4.9%)</td>
<td>1 (0.5%)</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>Pulmonary edema</td>
<td>5 (0.6%)</td>
<td>0</td>
<td>2 (1%)</td>
<td>0.496</td>
</tr>
<tr>
<td>Ascites</td>
<td>3 (0.3%)</td>
<td>0</td>
<td>1 (0.5%)</td>
<td>0.738</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>0</td>
<td>0</td>
<td>1 (0.5%)</td>
<td>0.072</td>
</tr>
<tr>
<td>Abruptio placentae</td>
<td>64 (7.1%)</td>
<td>10 (8.1%)</td>
<td>18 (9.2%)</td>
<td>0.581</td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td>617 (68.3%)</td>
<td>105 (86.3%)</td>
<td>150 (76.5%)</td>
<td>0.005</td>
</tr>
<tr>
<td>Maternal death</td>
<td>1 (0.1%)</td>
<td>0</td>
<td>1 (0.5%)</td>
<td>0.407</td>
</tr>
</tbody>
</table>

*According to the $\chi^2$ test for trend
maternal outcomes for women with HELLP syndrome and eclampsia were higher than those for women with severe preeclampsia (14.8% vs. 12.2% vs. 3.9%, respectively) (p=0.000). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Fetal findings are presented in Table 3. Birth weights were lower in infants of patients with HELLP syndrome than in infants of those with eclampsia or severe preeclampsia (p=0.005). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Fetal findings are presented in Table 3. Birth weights were lower in infants of patients with HELLP syndrome than in infants of those with eclampsia or severe preeclampsia (p=0.005). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Fetal findings are presented in Table 3. Birth weights were lower in infants of patients with HELLP syndrome than in infants of those with eclampsia or severe preeclampsia (p=0.005). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Fetal findings are presented in Table 3. Birth weights were lower in infants of patients with HELLP syndrome than in infants of those with eclampsia or severe preeclampsia (p=0.005). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Fetal findings are presented in Table 3. Birth weights were lower in infants of patients with HELLP syndrome than in infants of those with eclampsia or severe preeclampsia (p=0.005). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Fetal findings are presented in Table 3. Birth weights were lower in infants of patients with HELLP syndrome than in infants of those with eclampsia or severe preeclampsia (p=0.005). The rate of abruptio placentae tended to be higher among women with HELLP syndrome than among women with severe preeclampsia and eclampsia, but the difference was not significant (9.1% vs. 8.1% vs. 7.1%; p=0.581). Two maternal deaths occurred, producing a case fatality rate of 0.2% (one in the HELLP syndrome group and another in the severe preeclampsia group). Death was related to intracranial hemorrhage in one case and to an ARDS complication in another case.

Discussion

We examined maternal and perinatal outcomes for severe preeclampsia, eclampsia, and HELLP syndrome and found the following. 1) The mean gestational age and birth weight at delivery in the HELLP syndrome group were lower than those in the severe preeclampsia and eclampsia groups. 2) No significant differences were found for neonatal mortality and morbidity. 3) Abruptio placentae tended to be higher among women with HELLP syndrome than in the other groups, but the difference was not significant. 4) Perinatal and fetal mortality tended to be higher in the severe preeclampsia group than in the HELLP syndrome and eclampsia groups, but the difference was not significant (p=0.231).
tality at ≤32 weeks for patients with severe preeclampsia and HELLP syndrome was higher than that in the eclampsia group.

6) Significantly higher maternal morbidity was observed in the HELLP syndrome group than that in the other groups.

Primaparous young women with low socioeconomic status are the most typical preeclamptic and eclamptic cases. Our study also revealed clinical and sociodemographic data similar to the patient profiles in the extant literature. Most of these patients had had no regular antenatal visits, were primiparous, and young. HELLP syndrome has classically been described as a disease process that occurs more often in older, multigravid women than in younger nulliparous women with typical preeclampsia (13, 14). In our study, maternal age, gravity, and parity were higher in patients in HELLP syndrome than in those with severe preeclampsia and eclampsia, which agreed with a previous study (12).

Pregnancies complicated by severe preeclampsia/eclampsia or HELLP syndrome are associated with an increased risk for maternal morbidity and mortality. Complications leading to maternal morbidity include severe bleeding from abruptio placentae, pulmonary edema, ARF, cerebrovascular hemorrhage, and liver rupture. These complications are usually seen in women who develop severe preeclampsia, eclampsia, or HELLP syndrome before 32 weeks gestation (14). Women with HELLP syndrome have an increased risk for adverse maternal outcome compared with those who have severe preeclampsia/eclampsia (10, 15). The differences in the outcomes observed in these studies may be related to the earlier gestation in women with HELLP syndrome than in women with severe preeclampsia/eclampsia. In this study, the overall adverse maternal outcome rate was 5.9%. Statistical differences were found among the three groups for all adverse maternal outcomes studied. As expected, HELLP syndrome was associated with an increased risk for adverse maternal outcome (14.8%) compared with the risk associated with severe preeclampsia/eclampsia.

ARF, the most common adverse outcome in our study, was noted in 0.33% of patients. HELLP syndrome is the most frequent cause leading to ARF during pregnancy (16, 17). As expected, we found that the most frequent cause of ARF during pregnancy was HELLP syndrome (10.7%), which agreed with previous studies (16, 17). Maternal deaths associated with hypertensive disorders of pregnancy assumed greater importance than etiologies that were previously more frequently encountered, such as infection and hemorrhage. In our study, maternal deaths were due to intracranial hemorrhage and ARDS.

It is generally accepted that perinatal and neonatal morbidity and mortality rates increase in pregnancies complicated by severe preeclampsia, eclampsia, or HELLP syndrome. Different perinatal morbidity and mortality rates are presented in the literature (18-20). Although neonatal morbidity was generally

### Table 4. Perinatal and neonatal outcomes of study groups

<table>
<thead>
<tr>
<th>Perinatal and neonatal outcomes</th>
<th>Severe Preeclampsia (n=123)</th>
<th>Eclampsia (n=903)</th>
<th>HELLP syndrome (n=196)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission to ICU, %</td>
<td>14.8</td>
<td>21.6</td>
<td>17.3</td>
<td>0.169*</td>
</tr>
<tr>
<td>Duration of ICU (d, median, Q1-Q3)</td>
<td>13.5 (6-23.7)</td>
<td>8 (3.2-26.7)</td>
<td>15 (9-32.5)</td>
<td>0.345*</td>
</tr>
<tr>
<td>RDS, %</td>
<td>13.2</td>
<td>19.5</td>
<td>16.0</td>
<td>0.169*</td>
</tr>
<tr>
<td>IVH grades 3 and 4, %</td>
<td>1.3</td>
<td>2.7</td>
<td>2.6</td>
<td>0.379*</td>
</tr>
<tr>
<td>NEC grades 2 and 3, %</td>
<td>4.1</td>
<td>4.4</td>
<td>7.7</td>
<td>0.159*</td>
</tr>
<tr>
<td>Sepsis, %</td>
<td>6.7</td>
<td>6.2</td>
<td>8.3</td>
<td>0.735*</td>
</tr>
<tr>
<td>Duration of hospitalization (d, median, Q1-Q3)</td>
<td>4 (2-12)</td>
<td>4 (3-15)</td>
<td>6 (3-15)</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Perinatal mortality, %</td>
<td>13.1</td>
<td>7.7</td>
<td>13.7</td>
<td>0.231*</td>
</tr>
<tr>
<td>≤32 weeks, %</td>
<td>36.5</td>
<td>15.4</td>
<td>36.4</td>
<td>0.034*</td>
</tr>
<tr>
<td>&gt;32 weeks, %</td>
<td>4.9</td>
<td>3.8</td>
<td>3.3</td>
<td>0.706*</td>
</tr>
<tr>
<td>Neonatal mortality, %</td>
<td>5.6</td>
<td>4.6</td>
<td>5.9</td>
<td>0.890*</td>
</tr>
<tr>
<td>≤32 weeks, %</td>
<td>21</td>
<td>11.4</td>
<td>21.6</td>
<td>0.415*</td>
</tr>
<tr>
<td>&gt;32 weeks, %</td>
<td>1.7</td>
<td>1.4</td>
<td>0.9</td>
<td>0.815*</td>
</tr>
<tr>
<td>&gt;28 days mortality, %</td>
<td>1.1</td>
<td>1.9</td>
<td>4.8</td>
<td>0.009*</td>
</tr>
</tbody>
</table>

*According to Kruskal–Wallis test (triple comparison) P<0.05

*Mann-Whitney U test P1 = Severe Preeclampsia versus Eclampsia, P2 = Severe preeclampsia versus HELLP Syndrome, P3 = Eclampsia versus HELLP Syndrome. Significant p value after Bonferroni correction <0.017

*According to $\chi^2$ test for trend
similar across groups in our study, perinatal mortality was higher in pregnancies complicated by HELLP syndrome or severe preeclampsia before 32 weeks of gestation due to an increased number of stillbirths. Interestingly, the eclampsia group performed somewhat better considering early (<32 weeks) fetal losses. This was probably due to more abdominal deliveries and fewer growth-restricted fetuses in the eclampsia group. The high number of patients in the study population who did not have regular prenatal follow-ups may explain the high fetal and perinatal mortality. These findings suggest that perinatal morbidity and mortality are gestational-age dependent rather than disease dependent in cases with severe preeclampsia, eclampsia, or HELLP syndrome. Magann et al. determined that fetal morbidity and mortality are dependent on gestational age and reported similar and nonsignificant relationships between HELLP syndrome, severe preeclampsia, and eclampsia (21). Romero et al. showed that the majority of neonatal complications are due to prematurity (22). Severe preeclampsia, eclampsia, or HELLP syndrome manifest on average between 32 and 34 weeks of gestation. It is common clinical practice that a 32-34-week pregnancy should be delivered immediately. Before 32-34 weeks, expectant management is generally possible for selected patients in a perinatal center (23). Steroids are administered to induce fetal lung maturity. We prefer aggressive management in cases involving HELLP syndrome and eclampsia. In our study, we determined a median gestational age of 34 weeks (range, 31.05-35.9 weeks) for the appearance of HELLP syndrome, which was lower than that for severe preeclampsia and eclampsia.

*Figure 1. Flow diagram of the study*

(*Patients with HELLP syndrome and eclampsia were evaluated in the eclampsia group. 41 cases of eclampsia experienced HELLP syndrome.*)
The rate of cesarean delivery increases with increased occurrence of hypertensive disorders during pregnancy (24). Vaginal delivery is recommended for severely preeclamptic cases in the absence of obstetric indications for a cesarean section. In our study, women with eclampsia were more likely to deliver by cesarean section than were those with HELLP syndrome or severe preeclampsia. Fetal distress was the most frequent indication for cesarean section.

In summary, as expected, this study demonstrated that pregnancies complicated by HELLP syndrome have significantly higher maternal morbidity than do those with severe preeclampsia and eclampsia. Perinatal and neonatal mortality as neonatal morbidity were similar among the groups. When an analysis was performed according to gestational age, a significant difference was observed in perinatal and fetal morbidity before compared with after 32 weeks of gestation. These findings indicate that perinatal and neonatal outcomes of severe preeclampsia, eclampsia, and HELLP syndrome are dependent on the gestational age of delivery and are not diagnosis dependent.

Conflict of interest
No conflict of interest was declared by the authors.

References

15. Audibert F, Friedman SA, Frangiéh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzyme levels, and low platelets) syndrome. Am J Obstet Gynecol 1996; 175: 460-4. [CrossRef]